echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > AAN2021·Epilepsy column quotes real-world research: a systematic review of the behavioral adverse reactions of Buwaxitam, Levetiracetam, Perampanel, and Topiramate

    AAN2021·Epilepsy column quotes real-world research: a systematic review of the behavioral adverse reactions of Buwaxitam, Levetiracetam, Perampanel, and Topiramate

    • Last Update: 2021-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Research background and purpose Behavior and mental adverse reactions can affect the quality of life of patients with epilepsy.
    It is not only a common cause of interruption of anti-epileptic drug treatment, but also has a negative impact on the quality of life of most patients with epilepsy.

    Therefore, it is important to consider when choosing anti-epileptic drugs.

    The purpose of this review is to understand the occurrence of behavioral adverse reactions (irritability, anger, and aggression) in patients with epilepsy treated with antiepileptic drugs including Buwaracetam, Levetiracetam, Perampanel, and Topiramate in real-world studies after marketing.
    Rate and the resulting treatment interruption rate.

    The research method searched the Cochrane Library, PubMed/MEDLINE and Embase databases from October 2018 to October 2019.

    The system evaluates the incidence of irritability, anger, and aggression of the four anti-epileptic drugs and the resulting treatment interruption rate, and calculates a weighted average when possible.

    Research results This systematic review included 42 studies and 7 clinical trial records, with a total of 1500 data, including 25 retrospective studies, 16 prospective and observational studies, and 1 cross-sectional study.

    ➤The incidence of behavioral adverse reactions of anti-epileptic drugs in real-world studies: As shown in Figure 1, the incidence of irritability, anger, and aggression: topiramate is lower than perampanel, levetiracetam, and brivaracetam .

     Figure 1 A summary of the incidence of irritability, anger, or aggression in patients with epilepsy treated with Buwaxitam, Levetiracetam, Perampanel, and Topiramate in a real-world study ➤ Anti-epileptic drugs in real-world studies due to poor behavior Treatment interruption rate caused by response: As shown in Figure 2, the treatment interruption rate due to irritability and aggression: topiramate is lower than levetiracetam and perampanel; no studies have reported the causes of these 4 antiepileptic drugs Rate of treatment interruptions caused by anger.

     Figure 2 In a real-world study, the treatment interruption rate of Buwaxitan, Levetiracetam, Perampanel, and Topiramate in the treatment of epilepsy patients due to irritability or aggression is summarized and discussed by the weighted average value.
    In clinical practice , Perampanel and Levetiracetam are more irritable than Buwaxitan and Topiramate.

    Perampanel often experienced anger, followed by Levetiracetam and Buwaxitan.

    Brivaracetam, levetiracetam, and perampanel are more prone to aggressive behavior than topiramate.

    Topiramate has multiple mechanisms of action, including acting on voltage-gated sodium channels, GABAA receptors, AMPA/KA receptors and carbonic anhydrase.
    All these mechanisms of action work together to exert anti-epileptic effects.
    Compared with other anti-epileptic drugs in this review, Topiramate has a lower incidence of behavioral adverse reactions.

    Conclusion This review focuses on describing the adverse reactions of irritability, anger and aggressive behavior in patients with epilepsy in the real world of clinical practice taking Buwaxitam, Levetiracetam, Perampanel, and Topiramate, which can help clinicians Understand the risk of behavioral adverse reactions to different antiepileptic drugs, so as to better discuss treatment options with epilepsy patients.

     Literature index: A, Bernhard J.
    Steinhoff, et al.
    "Behavioraladverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.
    " Epilepsy & Behavior 118.
    1(2021):107939.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.